Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Atopic Dermatitis
2016-005181-57Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in atopic dermatitis (AD), sponsored by GWT-TUD. Started Jan 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-005181-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005181-57.